Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins.
about
Ultrasensitive Detection and Quantification of Toxins for Optimized Diagnosis of Clostridium difficile InfectionClostridium difficile infection: molecular pathogenesis and novel therapeuticsNeutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domainA Review of Experimental and Off-Label Therapies for Clostridium difficile InfectionPassive immunity against human pathogens using bovine antibodies.Equine hyperimmune serum protects mice against Clostridium difficile spore challengeSerum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters.Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults.Perspectives on immunoglobulins in colostrum and milkA novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice.Survival of anti-Clostridium difficile bovine immunoglobulin concentrate in the human gastrointestinal tract.Toxin-specific antibodies for the treatment of Clostridium difficile: current status and future perspectives.Bovine immunoglobulin concentrate-clostridium difficile retains C difficile toxin neutralising activity after passage through the human stomach and small intestineHyperimmune bovine colostrum as a novel therapy to combat Clostridium difficile infectionIntravenous immunoglobulin therapy for severe Clostridium difficile colitisTranscutaneous immunization with Clostridium difficile toxoid A induces systemic and mucosal immune responses and toxin A-neutralizing antibodies in mice.Development and Validation of Digital Enzyme-Linked Immunosorbent Assays for Ultrasensitive Detection and Quantification of Clostridium difficile Toxins in StoolHuman monoclonal antibodies against Clostridium difficile toxins A and B inhibit inflammatory and histologic responses to the toxins in human colon and peripheral blood monocytes.New advances in the treatment of Clostridium difficile infection (CDI)Antibody-enhanced, Fc gamma receptor-mediated endocytosis of Clostridium difficile toxin AA DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A.Treatment of Recurrent Clostridium difficile DiarrheaAntibodies for treatment of Clostridium difficile infection.The host immune response to Clostridium difficile infectionImmune-based treatment and prevention of Clostridium difficile infection.Intravenous adenovirus expressing a multi-specific, single-domain antibody neutralizing TcdA and TcdB protects mice from Clostridium difficile infection.Bovine antibodies targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative.Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters.A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model.A Rapid, Accurate, Single Molecule Counting Method Detects Clostridium difficile Toxin B in Stool Samples.
P2860
Q26776411-3D8452DF-F075-4C9F-9D48-C2F5F98E0997Q26864237-1E510C38-5E2E-4BF5-97A1-037011959CF9Q28302768-05409E55-3402-4C2A-85F7-FF0C49BC937DQ30240264-4814DF31-7E82-47C8-9210-5E7D0F24AF79Q33640433-33FD1BB5-8BC9-4D5C-A622-07727CF610A5Q33865434-D2B09DFE-5A43-4E73-82FE-7EBF019C8B53Q34000146-29D98746-1CA1-486B-8F9F-4645CF3907B9Q34006013-06DACACC-8077-43A1-BA08-0761249D8C91Q34247980-FB1B158E-909F-490B-851C-4D0471167D26Q34315655-27F77C67-5AFB-4944-B637-33FC789D7B10Q35131944-F4FCA5AF-0B47-4575-8813-27AE18AB4D95Q35155775-F9C6E38E-81B5-4EC5-9CE4-420F66381545Q35353994-BD22D941-8C08-4874-A622-B3EB745D4038Q35661928-FCCBC7B2-BA18-49C1-A809-787BD5CA93B1Q35841034-7D6DFAF9-9320-4B96-9CFC-808E65C51EADQ35913487-81D84144-E547-4676-BE3E-D1EE0CD87D88Q36066827-BAA01F92-018E-48FC-BF45-2C6A1C1AA63EQ36969841-DAB6C5A2-3DD5-4049-AFE7-55CAE989AC2FQ37052819-63F0C33C-5E4B-4D7C-9575-078E32F24499Q37204536-C82F7BE6-A0EE-4F0E-964B-7946CF02C1AFQ37258250-48350C13-8951-4FF9-A25B-4378974F53EFQ37678919-E5DE82B7-DA11-434C-9A1C-D52FF0AE2AD3Q38208794-8A469E09-E459-46BF-9910-63840C5E1E0CQ38244134-7CB2958D-A276-43F4-B8AA-3DBE04D54357Q38350907-2945A5AA-04FC-4FA7-8EF2-0C5FB90429ACQ38753004-A8CCE86F-77F3-43D7-8231-5637564F1B42Q40169068-6B0EA8FC-56A1-4042-AEFD-7636FAB1DBEFQ40233154-7751FA28-F3E9-4C8F-B168-7D87555CAE05Q41434690-17698119-6FAD-4CD3-AB47-25D644858632Q54985770-40916887-113A-4137-AA31-C04B29092556
P2860
Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins.
description
1996 nî lūn-bûn
@nan
1996 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Anti-Clostridium difficile bov ...... xicity of C. difficile toxins.
@ast
Anti-Clostridium difficile bov ...... xicity of C. difficile toxins.
@en
type
label
Anti-Clostridium difficile bov ...... xicity of C. difficile toxins.
@ast
Anti-Clostridium difficile bov ...... xicity of C. difficile toxins.
@en
prefLabel
Anti-Clostridium difficile bov ...... xicity of C. difficile toxins.
@ast
Anti-Clostridium difficile bov ...... xicity of C. difficile toxins.
@en
P2093
P2860
P356
P1476
Anti-Clostridium difficile bov ...... oxicity of C. difficile toxins
@en
P2093
C Pothoulakis
E F Bostwick
I Castagliuolo
J C O'Keane
J T LaMont
P2860
P304
P356
10.1128/AAC.40.2.373
P407
P577
1996-02-01T00:00:00Z